17:14 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Constellation raises $60M in NASDAQ IPO

Epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $60 million on July 18 through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital Markets and Oppenheimer....
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
00:51 , Jul 19, 2018 |  BC Extra  |  Financial News

Constellation slips after pricing $60M IPO

Constellation Pharmaceuticals Inc. (NASDAQ:CNST) dipped $3.52 (23%) to $11.48 Thursday after it raised $60 million through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital...
17:40 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting EZH2 or promoting FOXC1 expression could help treat the luminal B subtype of metastatic breast cancer. In patients with luminal B-type breast cancer, low...
21:39 , Jun 23, 2018 |  BC Extra  |  Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
22:43 , Apr 23, 2018 |  BC Extra  |  Clinical News

FDA places hold on Epizyme's tazemetostat

Epizyme Inc. (NASDAQ:EPZM) fell $2.90 (19%) to $12.40 in after-hours trading Monday after FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma...
13:42 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Constellation raises $100M

Cancer epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $100 million on April 9 in an untranched venture round from new investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed and...
10:59 , Apr 9, 2018 |  BC Extra  |  Financial News

Constellation raises $100M venture round

Cancer epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $100 million in an untranched venture round from new investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed and Sirona Capital. Existing...
10:55 , Apr 9, 2018 |  BioCentury  |  Finance

Epigenetic experience

Constellation Pharmaceuticals Inc.’s scientific team and deep epigenetics pipeline enabled the company to garner an untranched $100 million venture round. New investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed Advisors and...
20:37 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Constellation begins Phase Ib/II PROSTAR trial of CPI-1205

Constellation Pharmaceuticals Inc. (Cambridge, Mass.) began the Phase Ib/II PROSTAR trial evaluating CPI-1205 plus Xtandi enzalutamide and CPI-1205 plus Zytiga abiraterone and prednisone to treat metastatic castration-resistant prostate cancer (mCRPC). The Phase Ib portion will assess...